Details for Patent: 9,549,938

Title:	Boron-containing small molecules
Abstract:	This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Inventor(s):	Baker; Stephen J. (Collegeville, PA), Akama; Tsutomu (Sunnyvale, CA), Hernandez; Vincent S. (Watsonville, CA), Hold; Karin M. (Belmont, CA), Maples; Kirk (San Jose, CA), Plattner; Jacob J. (Berkeley, CA), Sanders; Virginia (San Francisco, CA), Zhang; Yong-Kang (San Jose, CA), Fieldson; Gregory T. (Morgantown, WV), Leyden; James J. (Malvern, CA)
Assignee:	Anacor Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:	Mar 11, 2016
Application Number:	15/068,352
Claims:	1. A method of treating a Tinea unguium infection of a toenail of a human, the method comprising: topically administering to the toenail of the human a pharmaceutical composition comprising 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole or a pharmaceutically acceptable salt thereof in an amount sufficient to treat the infection. 2. The method of claim 1, wherein the Tinea unguium infection is due to Trichophyton rubrum or Trichophyton mentagrophytes. 3. The method of claim 1, wherein the pharmaceutical composition is in the form of a solution comprising 5% w/w of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole. 4. The method of claim 1, wherein the pharmaceutical composition further comprises ethanol and propylene glycol. 5. The method of claim 1, wherein the Tinea unguium infection is due to Trichophyton rubrum or Trichophyton mentagrophytes, and wherein the pharmaceutical composition is in the form of a solution comprising 5% w/w of 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole. 6. The method of claim 5, wherein the pharmaceutical composition further comprises ethanol and propylene glycol.